Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Dec 06, 2012
Enrollment for a Global Confirmatory Phase 3 Clinical Trial Planned for 1Q13
Additional Formats
Supporting Materials
Nov 06, 2012
SOUTH PLAINFIELD, NJ – November 6, 2012 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Geoffrey McDonough, M.D., to the company's Board of Directors. Dr. McDonough is the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a leading European specialty
Additional Formats
Oct 22, 2012
SOUTH PLAINFIELD, NJ – October 22, 2012 – PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to discover antiviral agents for the treatment of dengue
Additional Formats
Sep 28, 2012
PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors SOUTH PLAINFIELD, NJ – September 28, 2012 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Jerome B. Zeldis, M.D., Ph.D., to the company's Board of Directors. Dr.
Additional Formats
Jul 23, 2012
PTC THERAPEUTICS CLOSES $30 MILLION FINANCING   SOUTH PLAINFIELD, NJ – July 23, 2012 – PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures,
Additional Formats
Jul 11, 2012
- PTC Receives $2.3 Million Payment -
Additional Formats
Jun 27, 2012
  SOUTH PLAINFIELD, NJ – June 27, 2012 – PTC Therapeutics, Inc. (PTC) today announced the initiation of an open-label study in the European Union, Israel, Australia and Canada for patients with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who received ataluren in a prior,
Additional Formats
Jun 08, 2012
- Data Demonstrate Positive Trends in Lung Function and Pulmonary Exacerbations -
Additional Formats
Apr 02, 2012
SOUTH PLAINFIELD, NJ – April 2, 2012 - PTC Therapeutics, Inc. (PTC) today announced the promotions of Cláudia Hirawat to President and Mark Boulding to Executive Vice President and Chief Legal Officer. "I am extremely pleased to announce these promotions.
Additional Formats
Dec 22, 2011
- Second PTC Discovery Program Funded by Seeding Drug Discovery Award -
Additional Formats